Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Bristol-Myers Squibb Hits 4-week Low
Why Bristol-Myers Squibb (BMY) Is Among the Best Long-Term Dividend Stocks to Invest in Right Now
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
Bristol-Myers Squibb To Go Ex-Dividend On January 3rd, 2025 With 0.62 USD Dividend Per Share
December 11th (Eastern Time) - $Bristol-Myers Squibb(BMY.US)$ is trading ex-dividend on January 3rd, 2025.Shareholders of record on January 3rd, 2025 will receive 0.62 USD dividend per share on
Bristol-Myers Squibb Boosts Quarterly Dividend $0.02 to $0.62 a Share, Payable Feb. 3 to Investors of Record Jan. 3
Press Release: Bristol Myers Squibb Announces Dividend Increase
Bristol Myers Squibb Announces Dividend Increase >BMY
Berenberg Bank Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60
Berenberg Bank Remains a Hold on Bristol-Myers Squibb (BMY)
BofA Restarts Coverage of 11 Large-cap Biopharmas
Bristol Myers Stock Surges 36.5% in Six Months: Time to Buy or Sell?
B of A Securities Reinstates Neutral on Bristol-Myers Squibb, Announces $63 Price Target
Bristol-Myers Squibb Analyst Ratings
BMO Capital Downgrades Bristol-Myers Squibb(BMY.US) to Hold Rating, Maintains Target Price $61
Bristol-Myers Squibb: Balancing Stability and Competition With Cautious Optimism
Express News | Bristol-Myers Squibb Co : Berenberg Raises Target Price to $60 From $55
Express News | Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at Ash 2024 With Long-Term Survival Data and Results From Expanding Pipeline
Jumo Health Is Fierce DEI Award Finalist for Remarkable Achievement, Positive Change in Healthcare
Unusual Options Activity: MTDR, NEE and Others Attract Market Bets, MTDR V/OI Ratio Reaches 177.8
EST Dec 6th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options